Friday, April 29, 2016

Ocular Therapeutix to initiate Phase 3 program with OTX-TP

Ocular Therapeutix to initiate Phase 3 program with OTX-TP

April 27, 2016 by · Leave a Comment 

Tweet Ocular Therapeutix (NASDAQ:OCUL) has completed an end-of-Phase 2 review with the FDA for its sustained release travoprost product candidate, OTX-TP, for the treatment of glaucoma and ocular hypertension and intends to initiate the first of two Phase 3 clinical trials during the third quarter of 2016. The FDA has stated that it agrees with […]

In conversation with Paul Gunn

In conversation with Paul Gunn

April 26, 2016 by · Leave a Comment 

http://www.youtube.com/watch?v=Acau04X2Utk’]

Tweet As president and CEO of closely-held Soricimed Biopharma, Paul Gunn parlayed a 20-year career as a financial executive into funding the startup of Soricimed along with a tech transfer in 2005 facilitated by Mount Allison University in Sackville, New Brunswick, Canada. Admittedly, he was new to biotech and drug development in those days, but […]

Opioid addiction treatment continues to grab headlines

Opioid addiction treatment continues to grab headlines

April 22, 2016 by · Leave a Comment 

Tweet An article in the latest issue of Guernica, a magazine of art and politics, details the plight of doctors prescribing buprenorphine, a medication for the treatment of opiate addiction. Unlike methadone, buprenorphine was approved for use in a general office setting. A doctor can apply to get a waiver to prescribe buprenorphine and treat […]

BTIG ups Cerus price target to $10

BTIG ups Cerus price target to $10

April 22, 2016 by · Leave a Comment 

Tweet BTIG Research has raised its price target for Cerus (NASDAQ:CERS) to $10 from $8, saying the progress made by the company has “exceeded even our bullish expectations.” The stock closed at $6.65 on Thursday. Cerus is a biomedical products company focused on the field of blood safety. “We are now lowering our discount rate […]

FDA rejects TransEnterix SurgiBot submission

FDA rejects TransEnterix SurgiBot submission

April 20, 2016 by · Leave a Comment 

Tweet The FDA has advised TransEnterix (NYSE MKT:TRXC) that its SurgiBot System does not meet the criteria for substantial equivalence based on the data and information submitted by the company in its 510(k) submission. “The FDA’s decision is extremely disappointing. We are in the process of reviewing all aspects of the FDA’s communication,” Todd Pope, […]

Rodman starts Bio-Path at buy

Rodman starts Bio-Path at buy

April 19, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has launched coverage of Bio-Path Holdings (NASDAQ:BPTH) with a “buy” rating and a 12-month price target of $5. The stock closed at $2.76 on Monday. “In our view, Bio-Path’s unique liposomal delivery of antisense DNA has the potential to significantly improve treatment outcomes in elderly patients (≥60 years) with acute myeloid […]

Xagenic readies X1 molecular diagnostic beta trials

Xagenic readies X1 molecular diagnostic beta trials

April 19, 2016 by · Leave a Comment 

Tweet Closely-held Xagenic plans to conduct beta studies this year, in advance of a major chlamydia and gonorrhea clinical trial, with its rapid X1 molecular diagnostic testing system in preparation for market launches in Europe and the U.S. “The Xagenic X1 platform is a revolutionary diagnostic sys­tem that allows the user to perform lab-quality molecular […]

Titan Pharma presents Phase 3 Probuphine data

Titan Pharma presents Phase 3 Probuphine data

April 15, 2016 by · Leave a Comment 

Tweet Titan Pharmaceuticals (NASDAQ:TTNP) has presented data from the last Phase 3 study of Probuphine, a six month subdermal buprenorphine implant for the long-term maintenance treatment of opioid addiction, at a poster session during the 47th Annual American Society of Addiction Medicine Annual Conference. The data indicate that participants who were clinically stable on sublingual […]

BTIG starts Senseonics Holdings at buy

BTIG starts Senseonics Holdings at buy

April 12, 2016 by · Leave a Comment 

Tweet BTIG Research has launched coverage of Senseonics Holdings (NYSE MKT:SENS) with a “buy” rating and 12-month price target of $4.50. The stock closed at $2.97 on Monday. “This may be a better way to monitor glucose if some hurdles are cleared,” writes analyst Dr. Sean Lavin, referring to the company’s implantable continuous glucose monitor […]

GMP starts Profound Medical at speculative buy

GMP starts Profound Medical at speculative buy

April 12, 2016 by · Leave a Comment 

Tweet GMP Securities has initiated coverage of Profound Medical (TSX-V:PRN) with a “speculative buy” rating and price target of $2. The stock closed at $1.50 on Monday. The company is focused on developing and commercializing an innovative therapy for the ablation of prostate cancer tissue, using real-time MRI to greatly improve accuracy, while reducing side […]

Next Page »

Email Newsletters with Constant Contact
Google+